Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.78 |
| ▸ | HPGD | P15428 | 6/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | RECQL | P46063 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21629521 | 0.91 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL13780769 | 0.90 | ALDH1A1 (0.74) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL21629593 | 0.89 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL13780692 | 0.89 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL21629570 | 0.88 | ALDH1A1 (0.79) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL21629541 | 0.88 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ERECQLKMT2A | |
| SCHEMBL21629540 | 0.88 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ERECQLKMT2A | |
| SCHEMBL13780714 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL21629562 | 0.86 | ALDH1A1 (0.76) | ALDH1A1HPGDKDM4ERECQLGAA | |
| SCHEMBL21629599 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDKDM4ERECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | ENGASE, NEU1, NEU2 | ALDH1A1 867/4885HPGD 754/4885KDM4E 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.